Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK -rearranged lung cancer

Cancer Discovery

Volumn 6, Issue 10, 2016, Pages 1118-1133

  Gainor, Justin F ^a   Dardaei, Leila ^a   Yoda, Satoshi ^a   Friboulet, Luc ^a,b   Leshchiner, Ignaty ^c   Katayama, Ryohei ^a,d   Dagogo Jack, Ibiayi ^a   Gadgeel, Shirish ^e   Schultz, Katherine ^a   Singh, Manrose ^a   Chin, Emily ^a   Parks, Melissa ^a   Lee, Dana ^a   DiCecca, Richard H ^a   Lockerman, Elizabeth ^a   Huynh, Tiffany ^a   Logan, Jennifer ^a   Ritterhouse, Lauren L ^a   Le, Long P ^a   Muniappan, Ashok ^a   Digumarthy, Subba ^a   Channick, Colleen ^a   Keyes, Colleen ^a   Getz, Gad ^c   Dias Santagata, Dora ^a   Heist, Rebecca S ^a   Lennerz, Jochen ^a   Sequist, Lecia V ^a   Benes, Cyril H ^a   Iafrate, A John ^a   Mino Kenudson, Mari ^a   Engelman, Jeffrey A ^a   Shaw, Alice T ^a   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d CANCER CHEMOTHERAPY CENTER   (Japan)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; BRIGATINIB; CRIZOTINIB; LORLATINIB; 7-AMINO-12-FLUORO-2,10,16-TRIMETHYL-15-OXO-10,15,16,17-TETRAHYDRO-2H-8,4-(METHENO)PYRAZOLO(4,3-H)(2,5,11)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE; CERITINIB; MACROCYCLIC LACTAM; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; SULFONE;

ARTICLE; BIOPSY; CLINICAL ASSESSMENT; EPITHELIAL MESENCHYMAL TRANSITION; GENE FREQUENCY; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MAJOR CLINICAL STUDY; SMALL CELL LUNG CANCER; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; MUTATION; NON SMALL CELL LUNG CANCER; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; LACTAMS, MACROCYCLIC; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SULFONES;

EID: 84994065677     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-0596     Document Type: Article

References (53)

1. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4–ALK fusion gene in non–small-cell lung cancer. Nature 2007; 448: 561–6.
2. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27: 4247–53.
3. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer. N Engl J Med 2010; 363: 1693–703.
4. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371: 2167–77.
5. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, e t al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385–94.
6. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, et al. Mechanisms of acquired crizotinib resistance in ALKrearranged lung cancers. Sci Transl Med 2012; 4: 120ra117.
7. Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012; 18: 1472–82.
8. Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 2013; 31: 3987–96.
9. Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med 2014; 20: 1027–34.
10. Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 2014; 346: 1480–6.
11. Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, B lakely CM, et al. RAS–MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med 2015; 21: 1038–47.
12. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014; 370: 1189–97.
13. Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, et al. Activity and safety of ceritinib in patients with ALK-rearranged nonsmall- cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol 2016; 17: 452–63.
14. Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, et al. Alectinib in crizotinib-refractory ALK-rearranged non–small-cell lung cancer: a phase II global study. J Clin Oncol 2016; 34: 661–8.
15. Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, et al. Alectinib in ALK-positive, crizotinib-resistant, non–small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 2016; 17: 234–42.
16. Camidge D, Bazhenova L, Salgia R, Langer CJ, Gold KA, Rosell R, et al. Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK + non–small cell lung cancer (NSCLC). J Clin Oncol 33, 2015 (suppl; abstr 8062).
17. Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in nonsmall cell lung cancer. Cancer Discov 2014; 4: 662–73.
18. Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011; 19: 679–90.
19. Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, et al. P-glycoprotein mediates ceritinib resistance in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. EBioMedicine 2016; 3: 54–66.
20. Isozaki H, Ichihara E, Takigawa N, Ohashi K, Ochi N, Yasugi M, et al. Non–small cell lung cancer cells acquire resistance to the ALK inhibitor alectinib by activating alternative receptor tyrosine kinases. Cancer Res 2016; 76: 1506–16.
21. Toyokawa G, Inamasu E, Shimamatsu S, Yoshida T, Nosaki K, Hirai F, et al. Identification of a novel ALK G1123S mutation in a patient with ALK-rearranged non–small-cell lung cancer exhibiting resistance to ceritinib. J Thorac Oncol 2015; 10: e55–7.
22. Ignatius Ou SH, Azada M, Hsiang DJ, Herman JM, Kain TS, Siwak- Tapp C, et al. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALKrearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol 2014; 9: 549–53.
23. Ou SH, Milliken JC, Azada MC, Miller VA, Ali SM, Klempner SJ. ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression. Lung Cancer 2016; 91: 70–2.
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canda. J Natl Cancer Inst 2000; 92: 205–16.
25. Zou HY, Friboulet L, Kodack DP, Engstrom LD, Li Q, West M, et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell 2015; 28: 70–81.
26. Zhang S, Wang F, Keats J, Zhu X, Ning Y, Wardwell SD, et al. Crizotinib- resistant mutants of EML4–ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des 2011; 78: 999–1005.
27. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford D, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–47.
28. Ou SH, Greenbowe J, Khan ZU, Azada MC, Ross JS, Stevens PJ, et al. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib. Lung Cancer 2015; 88: 231–4.
29. Katayama R, Friboulet L, Koike S, Lockerman EL, Khan TM, Gainor JF, et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res 2014; 20: 5686–96.
30. Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007; 117: 2562–9.
31. Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M. Nat Med 2015; 21: 560–2.
32. Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res 2015; 21: 3924–33
33. Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Berggvist S, Brooun A, et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med 2016; 374: 54–61.
34. Tyner JW, Fletcher LB, Wang EQ, Yang WF, Rutenberg-Schoenberg ML, Beadling C, et al. MET receptor sequence variants R970C and T992I lack transforming capacity. Cancer Res 2010; 70: 6233–7.
35. Rudd ML, Price JC, Fogoros S, Godwin AK, Sgroi DC, Merino M J, et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res 2011; 17: 1331–40.
36. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26.
37. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2010; 2: 146–58.
38. Zhang S, Wang F, Keats J, Ning Y, Wardwell SD, Moran L, et al. Abstract LB-298: AP26113, a potent ALK inhibitor, overcomes mutations in EML4–ALK that confer resistance to PF-02341066 (PF1066). Cancer Res 2010; 70: LB–298.
39. Toyokawa G, Hirai F, Inamasu E, Yoshida T, Nosaki K, Takenaka T, et al. Secondary mutations at I1171 in the ALK gene confer resistance to both crizotinib and alectinib. J Thorac Oncol 2014; 9: e86–7.
40. Bauer RC, Sänger J, Peschel C, Duyster J, von Bubnoff N. Sequential inhibitor therapy in CML: in vitro simulation elucidates the pattern of resistance mutations after second- and third-line treatment. Clin Cancer Res 2013; 19: 2962–72.
41. Yu HA, Tian SK, Drilon AE, Borsu L, Riely GJ, Arcila ME, et al. Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain. JAMA Oncol 2015; 1: 982–4.
42. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial–mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15: 178–96.
43. Gower A, Hsu WH, Hsu ST, Wang Y, Giaccone G. EMT is associated with, but does not drive resistance to ALK inhibitors among EML4–ALK non–small cell lung cancer. Mol Oncol 2016; 10: 601–9.
44. Guo F, Liu X, Qing Q, Sang Y, Feng C, Li X, et al. EML4-ALK induces epithelial–mesenchymal transition consistent with cancer stem cell properties in H1299 non–small cell lung cancer cells. Biochem Biophys Res Commun 2015; 459: 398–404.
45. Kim HR, Kim WS, Choi YJ, Choi CM, Rho JK, Lee JC. Epithelialmesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation. Mol Oncol 2013; 7: 1093–102
46. Fujita S, Masago K, Katakami N, Yatabe Y. Transformation to SCLC after treatment with the ALK inhibitor alectinib. J Thorac Oncol 2016; 11: e67–72.
47. Cha YJ, Cho BC, Kim HR, Lee HJ, Shim HS. A case of ALK-rearranged adenocarcinoma with small cell carcinoma-like transformation and resistance to crizotinib. J Thorac Oncol 2016; 11: e55–8.
48. Miyamoto S, Ikushima S, Ono R, Awano N, Kondo K, Furuhata Y, et al. Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib. Jpn J Clin Oncol 2016; 46: 170–3.
49. Solomon B, Bauer T, Felip E, Besse B, James LP, Clancy JS, et al. Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK + or ROS1 + non–small cell lung cancer (NSCLC). J Clin Oncol 34, 2016 (suppl; abstr 9009).
50. Gainor JF, Tan DS, De Pas T, Solomon BJ, Ahmad A, Lazzari C, et al. Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib. Clin Cancer Res 2015; 21: 2745–52.
51. Piotrowska Z, Niederst MJ, Karlovich CA, Wakelee HA, Neal JW, Mino-Kenudson M, et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov 2015; 5: 713–22.
52. Zheng Z, Liebers M, Zhelyazkova B, Cao Y, Panditi D, Lynch KD, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med 2014; 20: 1479–84.
53. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31: 1023–31.